Menstrual Cycle and Hormonal Regulation - Anatomy and Physiology

SECTION 1

Historical Context & Motivation

The biological basis of the menstrual cycle remained largely mysterious until the twentieth century, when advances in endocrinology allowed researchers to isolate and characterize the hormones responsible for cyclical reproductive changes. Ancient physicians—Hippocrates, Galen, and Soranus among them—recognized menstruation as a recurring phenomenon, yet their explanations relied on humoral theory rather than endocrine signaling. The transition from speculative frameworks to the modern understanding of hypothalamic–pituitary–gonadal (HPG) axis control represents one of the great achievements of reproductive biology.

1905 • The Hormone Concept

Ernest Starling coined the term hormone to describe chemical messengers that travel through the bloodstream to exert distant effects, providing the conceptual foundation for understanding menstrual regulation.

1929 • Isolation of Estrogen

Edward Doisy and Adolf Butenandt independently isolated estrone, the first estrogen to be chemically characterized, confirming that ovarian secretions drive uterine changes.

1934 • Progesterone Identified

Four research groups—including those of Butenandt and Allen—crystallized progesterone from corpus luteum tissue, establishing its role in preparing the endometrium for implantation.

1971 • GnRH Characterized

Andrew Schally and Roger Guillemin determined the structure of gonadotropin-releasing hormone (GnRH), revealing the hypothalamic decapeptide that initiates the entire HPG cascade—work that earned them the 1977 Nobel Prize.

2000s • Kisspeptin Signaling Discovered

The discovery of kisspeptin (encoded by KISS1) as an upstream regulator of GnRH neurons provided a molecular explanation for the onset of puberty and the positive-feedback trigger of the LH surge.

Together, these discoveries raised a central question that remains the organizing framework for reproductive endocrinology: How does a single neuroendocrine axis generate both negative and positive feedback within a single cycle, producing precisely timed ovulation and endometrial preparation? Answering this question requires integrating anatomy, biochemistry, and systems-level thinking—exactly the approach this lesson develops.

SECTION 2

Core Principles of Hormonal Regulation

The menstrual cycle, averaging approximately 28 days though normally ranging from 21 to 35 days, is governed by a hierarchical endocrine cascade that begins in the hypothalamus and terminates in the ovary and uterus. Understanding the cycle requires mastery of several foundational principles that explain how hormones communicate across organ systems through both stimulatory and inhibitory signaling loops.

Hypothalamic–Pituitary–Gonadal Axis

The HPG axis is a three-tier hormonal cascade: GnRH from the hypothalamus stimulates the anterior pituitary to release FSH and LH, which in turn act on the ovaries to drive folliculogenesis, steroidogenesis, and ovulation.

Negative Feedback

For most of the cycle, rising levels of estradiol and inhibin B suppress GnRH pulse frequency and FSH secretion respectively, preventing premature gonadotropin surges and ensuring single-follicle dominance.

Positive Feedback (The LH Surge)

When estradiol exceeds approximately 200 pg/mL for ≥ 48 hours, the feedback switches from inhibitory to stimulatory, triggering the massive LH surge that induces ovulation—a rare example of positive feedback in endocrine physiology.

Two-Cell, Two-Gonadotropin Model

LH stimulates theca cells to produce androgens, while FSH drives granulosa cells to aromatize those androgens into estradiol. Neither cell type alone can produce sufficient estrogen—cooperation is essential.

Pulsatile GnRH Secretion

GnRH must be released in pulsatile fashion to maintain pituitary responsiveness. Rapid pulses (~every 60 min) favor LH release, while slower pulses (~every 90–120 min) favor FSH release, providing a frequency-encoded signal that shifts across the cycle.

✦

KEY TAKEAWAY

Think of the HPG axis as a corporate chain of command with a twist: the CEO (hypothalamus) sends memos (GnRH) to middle management (anterior pituitary), which dispatches directives (FSH and LH) to the factory floor (ovaries). Normally, when production (estradiol) is high, workers send feedback up the chain to slow orders—classic negative feedback. But once output hits a critical threshold, the factory sends an urgent demand for even more resources—a brief positive feedback burst that triggers the LH surge and ovulation. This switch between inhibition and stimulation within a single signaling axis is the key puzzle of the menstrual cycle.

SECTION 3

Hormonal Profiles Across the 28-Day Cycle

The following diagram illustrates the temporal profiles of the four principal reproductive hormones—FSH, LH, estradiol, and progesterone—across a standard 28-day cycle. The x-axis represents cycle day (day 1 = onset of menstruation), and the y-axis represents relative serum concentration. Observe how the estradiol peak immediately precedes and triggers the LH surge around day 12–14, while progesterone dominates the luteal phase following ovulation.

Relative serum concentrations of FSH (cyan), LH (violet), estradiol (pink), and progesterone (amber) across a typical 28-day cycle. Note the estradiol peak preceding the LH surge around day 12–14, and the progesterone dominance of the luteal phase (days 15–28). The dashed line marks ovulation.

Several critical features deserve attention. First, FSH rises in the early follicular phase due to the withdrawal of estradiol and inhibin following corpus luteum regression; this rise recruits a cohort of antral follicles. Second, as the dominant follicle produces increasing amounts of estradiol, FSH is suppressed via negative feedback, causing atresia of competing follicles—a mechanism central to single-follicle selection. Third, the transition from negative to positive feedback at high, sustained estradiol concentrations represents a concentration- and duration-dependent switch at the level of the anterior pituitary and hypothalamic kisspeptin neurons, producing the explosive LH surge that triggers ovulation approximately 36 hours later. Finally, the post-ovulatory rise in progesterone from the corpus luteum prepares the endometrium for potential implantation and reinstates negative feedback that prevents a second ovulation.

SECTION 4

Mechanisms of the HPG Axis

While the menstrual cycle is not typically described with a single governing equation, several quantitative relationships underpin clinical and research approaches to reproductive endocrinology. The GnRH pulse generator in the arcuate nucleus of the hypothalamus fires in a frequency-modulated fashion. During the follicular phase, pulses occur approximately every 60–90 minutes; during the luteal phase, progesterone slows pulse frequency to every 120–240 minutes. This frequency encoding is essential because continuous GnRH administration, paradoxically, downregulates pituitary GnRH receptors and suppresses gonadotropin release—a principle exploited clinically by GnRH agonists used in fertility treatments and endometriosis management.

The Two-Cell, Two-Gonadotropin Model

Estradiol synthesis in the ovary requires cooperation between two distinct cell types. Theca interna cells express LH receptors and convert cholesterol to androgens (primarily androstenedione) via the enzyme CYP17 (17α-hydroxylase / 17,20-lyase). These androgens diffuse across the basement membrane to granulosa cells, which express FSH receptors and the enzyme aromatase (CYP19). Aromatase converts androstenedione to estrone and testosterone to estradiol-17β (E₂). This compartmentalized biosynthetic pathway means that neither cell type in isolation can produce significant quantities of estrogen.

STEROIDOGENIC PATHWAY SUMMARY

Cholesterol → Pregnenolone → DHEA → Androstenedione → (Aromatase) → Estrone / Estradiol

In theca cells, LH drives conversion of cholesterol to androstenedione via CYP11A1 and CYP17. In granulosa cells, FSH upregulates aromatase (CYP19), which catalyzes the A-ring aromatization of C₁₉ androgens to C₁₈ estrogens.

Feedback Switch: From Negative to Positive

The mechanism of the estradiol-induced positive feedback loop has been elucidated through studies of kisspeptin neurons in the anteroventral periventricular nucleus (AVPV) of the hypothalamus. At low-to-moderate estradiol levels, estrogen receptor alpha (ERα) signaling in arcuate kisspeptin neurons suppresses GnRH pulse amplitude—classic negative feedback. However, when estradiol rises above approximately 200 pg/mL and is sustained for at least 36–48 hours, ERα signaling in AVPV kisspeptin neurons activates a stimulatory pathway that dramatically increases GnRH release, driving the LH surge. This concentration- and duration-dependent switch is the molecular basis for the only physiological positive feedback loop in the HPG axis.

POSITIVE FEEDBACK THRESHOLD

E₂ ≥ 200 pg/mL for ≥ 36–48 h → AVPV kisspeptin ↑ → GnRH surge → LH surge → Ovulation

E₂ = serum estradiol-17β concentration. The threshold values represent approximate clinical ranges; individual variation exists. The LH surge typically lasts 48–50 hours, with ovulation occurring approximately 36 hours after surge onset.

ℹ

Clinical Connection

The principle that continuous GnRH suppresses gonadotropin release (via receptor downregulation) underlies the therapeutic use of GnRH agonists such as leuprolide. After an initial flare of LH and FSH, prolonged exposure desensitizes pituitary gonadotropes, creating a medical menopause useful for treating endometriosis, uterine fibroids, and precocious puberty, and for controlled ovarian hyperstimulation in IVF protocols.

SECTION 5

Phases of the Ovarian and Uterine Cycles

The menstrual cycle is best understood as two parallel, synchronized cycles: the ovarian cycle (follicular, ovulatory, and luteal phases) describing events in the ovary, and the uterine (endometrial) cycle (menstrual, proliferative, and secretory phases) describing concurrent changes in the endometrium. The ovarian hormones—estradiol and progesterone—are the signaling bridge between the two. The diagram below maps these parallel phases to one another and to the underlying hormonal environment.

Parallel timeline showing the three ovarian phases (follicular, ovulatory, luteal) aligned with the three uterine phases (menstrual, proliferative, secretory). The bottom panel indicates the dominant hormone driving each transition and a schematic representation of endometrial thickness changes.

Phase	Days (Approx.)	Ovarian Events	Uterine Events	Dominant Hormones
Menstrual / Early Follicular	1–5	FSH rise recruits cohort of 6–12 antral follicles; follicles grow from ~5 mm	Functional layer of endometrium is shed (menstruation); spiral arterioles constrict, then slough	FSH ↑; estradiol and progesterone at nadir
Late Follicular / Proliferative	6–13	Dominant follicle selected (~day 7); subordinate follicles undergo atresia; dominant follicle reaches ~18–20 mm	Estrogen-driven proliferation of endometrial glands, stroma, and spiral arteries; endometrium thickens to ~8–12 mm	Estradiol ↑↑; FSH ↓ (negative feedback); LH slowly rises
Ovulatory	~14 (36 h window)	LH surge triggers resumption of meiosis I, follicle wall rupture, and oocyte release with corona radiata	Transition from proliferative to secretory influence as progesterone begins to rise	LH surge (~48 h); FSH co-surge; estradiol dips briefly
Early Luteal / Secretory	15–21	Granulosa and theca cells luteinize → corpus luteum; progesterone and estradiol secretion increases	Endometrial glands become tortuous and secrete glycogen, glycoproteins; stromal edema; optimal implantation window ~days 20–24	Progesterone ↑↑; estradiol ↑; inhibin A ↑
Late Luteal	22–28	Without hCG rescue, corpus luteum undergoes luteolysis → corpus albicans; progesterone and estradiol fall	Withdrawal of progesterone → spiral arteriole spasm → ischemia → necrosis → menstruation restarts	Progesterone ↓↓; estradiol ↓; FSH begins to rise again

Summary of ovarian and uterine events across the five major sub-phases of the menstrual cycle

SECTION 6

Worked Example: Clinical Scenario Analysis

To integrate the hormonal principles discussed above, consider a clinical vignette that requires you to predict hormonal profiles and physiological outcomes based on the HPG axis model.

Predicting Ovulatory Status from Mid-Cycle Lab Values

1
Step 1 — Assess the Clinical Scenario

A 28-year-old patient presents on day 12 of her cycle. Lab results show: serum estradiol = 310 pg/mL, LH = 8 mIU/mL (baseline range 2–15 mIU/mL in follicular phase), progesterone = 0.8 ng/mL. Ultrasound reveals a dominant follicle measuring 19 mm in the right ovary. Question: Will ovulation likely occur, and if so, when?
2
Step 2 — Evaluate Estradiol Against Positive Feedback Threshold

The estradiol level of 310 pg/mL exceeds the approximate positive feedback threshold of 200 pg/mL. If this level has been sustained for at least 36–48 hours (consistent with a dominant follicle at 19 mm that has been producing estradiol for several days), the positive feedback switch should be engaged. This means the AVPV kisspeptin neurons are likely already stimulating increased GnRH secretion.

Estradiol exceeds threshold (310 pg/mL > 200 pg/mL) → positive feedback engaged.
3
Step 3 — Interpret Current LH Level

LH is currently 8 mIU/mL, within the normal follicular range. The LH surge has not yet begun (surge values typically exceed 25–40 mIU/mL). However, the hormonal conditions for the surge are in place: high sustained estradiol and a mature follicle. The surge is imminent—likely within 12–24 hours.

LH surge has not yet occurred but is imminent.
4
Step 4 — Confirm with Progesterone Level

Progesterone at 0.8 ng/mL confirms that ovulation has not yet occurred, since post-ovulatory luteal-phase progesterone typically exceeds 3 ng/mL and peaks at 10–20 ng/mL. A pre-ovulatory progesterone below 1.5 ng/mL is expected.

Low progesterone (0.8 ng/mL) confirms pre-ovulatory status.
5
Step 5 — Predict Timing of Ovulation

Given that the LH surge typically begins within 24 hours of sustained high estradiol and a mature follicle (≥18 mm), and ovulation occurs approximately 36 hours after surge onset, we can estimate that this patient will ovulate around day 14 ± 1 day of her cycle (approximately 48–60 hours from the current assessment on day 12).

Predicted ovulation: approximately cycle day 14 (within 48–60 hours of current assessment).

🔬

CLINICAL REASONING FRAMEWORK

When analyzing menstrual cycle lab values, always follow this sequence: (1) establish cycle day from history, (2) evaluate estradiol relative to the ~200 pg/mL positive feedback threshold, (3) assess whether LH is at baseline or surging, (4) check progesterone to confirm pre- vs. post-ovulatory status, and (5) correlate with ultrasound findings (follicle size ≥ 18 mm suggests imminent ovulation). This systematic approach applies equally to fertility assessments and to understanding anovulatory conditions such as PCOS.

SECTION 7

Clinical Correlates & Pathophysiology

Understanding normal menstrual cycle physiology provides the foundation for recognizing and treating common disorders of reproductive endocrinology. Disruption at any level of the HPG axis—hypothalamic, pituitary, or ovarian—can produce distinct clinical presentations. The table below compares several key conditions with their underlying hormonal derangements.

Condition	HPG Level Affected	Hormonal Profile	Key Clinical Features
Hypothalamic Amenorrhea	Hypothalamus	↓ GnRH pulse frequency/amplitude → ↓ FSH, ↓ LH, ↓ estradiol	Amenorrhea in athletes, patients with eating disorders, or extreme stress; low bone density risk
PCOS	Ovarian / Hypothalamic	↑ LH:FSH ratio (often > 2:1); ↑ androgens; ↑ or normal estrogen; ↓ progesterone (anovulation)	Oligomenorrhea or amenorrhea, hirsutism, acne, polycystic ovarian morphology, insulin resistance
Primary Ovarian Insufficiency	Ovary	↑↑ FSH, ↑ LH (loss of negative feedback); ↓ estradiol	Amenorrhea before age 40; hot flashes; infertility; elevated cardiovascular risk
Hyperprolactinemia	Pituitary / Hypothalamic	↑ Prolactin → ↓ GnRH pulses → ↓ FSH, ↓ LH, ↓ estradiol	Amenorrhea, galactorrhea; often due to pituitary adenoma or dopamine antagonist medications
Luteal Phase Defect	Ovary (corpus luteum)	↓ Progesterone in luteal phase; shortened luteal phase (< 11 days)	Recurrent early pregnancy loss; spotting before expected menses; inadequate endometrial maturation

Common disorders of the HPG axis and their hormonal signatures

🧩

DIAGNOSTIC LOGIC

When evaluating amenorrhea, the FSH level is the critical discriminator: high FSH indicates ovarian failure (the pituitary is screaming for follicular activity that the ovary cannot provide), whereas low or normal FSH with low estradiol indicates a hypothalamic or pituitary problem (the upstream signal is deficient). This distinction—analogous to differentiating a thermostat malfunction from a furnace failure—is the first branch point in reproductive endocrine workup.

SECTION 8

Connections to Advanced Reproductive Endocrinology

The menstrual cycle model presented in this lesson provides the essential framework upon which more advanced topics in reproductive biology are built. Understanding the normal 28-day cycle is a prerequisite for grasping the hormonal pharmacology of oral contraceptives, the physiology of pregnancy, and the molecular basis of assisted reproductive technologies (ART). The table below contrasts the foundational concepts covered here with their advanced extensions.

This Lesson	Advanced Extension	Key New Concepts
Positive feedback → LH surge → ovulation	Controlled ovarian hyperstimulation (COH) for IVF	Exogenous gonadotropins override negative feedback; GnRH antagonists prevent premature LH surges; trigger injection (hCG or GnRH agonist) replaces endogenous surge
Corpus luteum produces progesterone; luteolysis → menstruation	Rescue of corpus luteum by hCG in early pregnancy	Trophoblast-derived hCG mimics LH, maintaining corpus luteum until placental steroidogenesis takes over at ~8–10 weeks gestation
Negative feedback of estradiol + progesterone on GnRH/FSH/LH	Mechanism of combined oral contraceptives (COCs)	Exogenous ethinyl estradiol + progestin suppress GnRH pulses and prevent LH surge, inhibiting ovulation; thinner endometrium reduces implantation probability
Kisspeptin → GnRH → gonadotropins	Kisspeptin-based therapies for infertility and hypogonadism	Kisspeptin-54 injections can trigger LH surges in women with hypothalamic amenorrhea; potential alternative to hCG trigger in IVF to reduce OHSS risk
FSH-driven follicle selection and single dominance	Anti-Müllerian hormone (AMH) and ovarian reserve testing	AMH from small antral follicles reflects remaining follicle pool; used to predict COH response and estimate reproductive lifespan

Connections between foundational menstrual cycle physiology and advanced reproductive medicine

As you continue into reproductive endocrinology, notice how nearly every clinical intervention—from contraception to fertility treatment—is essentially a pharmacological manipulation of the feedback loops you have learned in this lesson. The negative feedback principle explains how oral contraceptives prevent ovulation; the positive feedback principle explains how clinicians can trigger ovulation with precisely timed hCG injections. Mastering the normal cycle gives you the conceptual toolkit to understand both pathology and therapy.

SECTION 9

Practice Problems

Question 1: CONCEPTUAL

Explain why continuous (non-pulsatile) administration of GnRH suppresses gonadotropin release rather than stimulating it. How is this pharmacological principle exploited clinically?

Show answer

Pituitary gonadotropes require pulsatile GnRH stimulation to maintain receptor density and signaling competence. Continuous GnRH exposure causes downregulation and internalization of GnRH receptors on the gonadotrope membrane, leading to desensitization. After an initial "flare" of FSH and LH release (lasting ~1–2 weeks), receptor downregulation produces a functional chemical castration. Clinically, GnRH agonists such as leuprolide exploit this phenomenon to suppress sex steroid production in endometriosis, uterine fibroids, prostate cancer, and precocious puberty.

Question 2: BASIC CALCULATION

A patient's serum estradiol is measured at 180 pg/mL on cycle day 11 and 250 pg/mL on cycle day 12. Is the positive feedback threshold likely met? Justify using the dual criteria (concentration and duration).

Show answer

The positive feedback threshold requires estradiol ≥ 200 pg/mL sustained for at least 36–48 hours. On day 11, estradiol is 180 pg/mL—below the threshold. By day 12, it has risen to 250 pg/mL, which exceeds 200 pg/mL. However, since only approximately 24 hours have elapsed since crossing 200 pg/mL (assuming a linear rise, the threshold was crossed sometime between day 11 and day 12), the duration criterion of 36–48 hours may not yet be met. The positive feedback switch is likely being primed but has probably not yet triggered the full LH surge. We would expect the LH surge to begin within the next 12–24 hours as the duration criterion is fulfilled.

Question 3: INTERMEDIATE

A patient with PCOS has the following labs: LH = 18 mIU/mL, FSH = 6 mIU/mL, testosterone = 85 ng/dL (elevated), estradiol = 60 pg/mL, progesterone = 0.4 ng/mL. She reports irregular periods every 45–60 days. Using the two-cell, two-gonadotropin model and feedback principles, explain why she has (a) elevated androgens, (b) relatively normal estradiol, and (c) low progesterone.

Show answer

(a) The elevated LH:FSH ratio (3:1 here) drives excessive androgen production by theca cells, since LH stimulates CYP17 and cholesterol side-chain cleavage in these cells. With disproportionately high LH, androstenedione and testosterone output increase beyond what granulosa cells can aromatize. (b) Despite the androgen excess, peripheral conversion of androgens by adipose-tissue aromatase and limited granulosa-cell aromatization maintain near-normal estradiol levels; however, the estradiol never reaches the sustained ≥ 200 pg/mL threshold needed for positive feedback because no dominant follicle matures sufficiently. (c) Without an LH surge, ovulation does not occur, so no corpus luteum forms, and progesterone remains at baseline follicular-phase levels. This chronic anovulation explains both the oligomenorrhea and the low progesterone. The chronically tonically elevated estrogen (without the cyclic progesterone opposition) also places the patient at risk for endometrial hyperplasia.

Question 4: APPLIED

A fertility specialist administers exogenous FSH (follitropin alfa) to a patient beginning on cycle day 3 to stimulate multi-follicular development for IVF. Predict the effects on: (1) follicle recruitment, (2) serum estradiol trajectory, (3) risk of a premature LH surge, and explain why a GnRH antagonist is co-administered starting around day 6.

Show answer

(1) Exogenous FSH overrides the normal single-follicle selection process: by keeping FSH above the threshold that would normally decline (due to negative feedback from the first dominant follicle), multiple follicles are "rescued" from atresia and continue to grow simultaneously. (2) Because multiple follicles are producing estradiol concurrently, serum estradiol rises much more steeply and to much higher levels than in a natural cycle—often exceeding 1,000–3,000 pg/mL. (3) These supraphysiological estradiol levels would trigger premature positive feedback and an endogenous LH surge, causing uncontrolled ovulation before oocyte retrieval. The GnRH antagonist (e.g., cetrorelix or ganirelix) is started around day 6 to competitively block GnRH receptors on pituitary gonadotropes, preventing the LH surge while still allowing exogenous FSH to drive follicular growth. Ovulation is then triggered at the optimal time with an hCG injection that mimics the LH surge.

Question 5: CRITICAL THINKING

Combined oral contraceptives (COCs) contain both synthetic estrogen and progestin. Explain mechanistically why both components are necessary: what would happen if only the progestin were given (as in a progestin-only pill), and why might the estrogen component be important for cycle control? In your answer, address the effects on GnRH pulsatility, the LH surge, endometrial stability, and breakthrough bleeding.

Show answer

The progestin component is the primary ovulation suppressant: it slows GnRH pulse frequency (mimicking the luteal-phase pattern), reduces LH secretion, and prevents the mid-cycle LH surge. It also thickens cervical mucus and thins the endometrium. A progestin-only pill (POP) can prevent ovulation, but does so inconsistently—particularly at low doses—because without exogenous estrogen, residual FSH may still drive partial follicular development and estradiol production. The synthetic estrogen (typically ethinyl estradiol) adds several benefits: (1) it suppresses FSH more reliably via negative feedback, preventing follicular recruitment entirely; (2) it stabilizes the endometrium by providing a baseline estrogenic environment that, when combined with progestin, prevents the irregular shedding and breakthrough bleeding commonly seen with progestin-only methods; (3) it ensures predictable withdrawal bleeding during the placebo week, providing reassurance of non-pregnancy. Thus, the dual-component design exploits both negative feedback pathways simultaneously—estrogen suppressing FSH and folliculogenesis, progestin suppressing LH surge and altering endometrial receptivity—to achieve more reliable contraception and better cycle control than either component alone.

SUMMARY

Menstrual Cycle and Hormonal Regulation — Summary

Summary

The menstrual cycle is governed by the hypothalamic–pituitary–gonadal (HPG) axis, in which pulsatile GnRH from the hypothalamus drives anterior pituitary release of FSH and LH, which in turn stimulate the ovary via the two-cell, two-gonadotropin model: LH drives theca-cell androgen production, and FSH drives granulosa-cell aromatization to estradiol. For most of the cycle, rising estradiol exerts negative feedback on FSH and LH, ensuring single-follicle dominance. However, when estradiol exceeds ~200 pg/mL for ≥ 36–48 hours, kisspeptin neurons in the AVPV switch the signal to positive feedback, generating the LH surge that triggers ovulation.

The cycle divides into parallel ovarian and uterine phases: the follicular phase (estrogen-driven follicle growth and endometrial proliferation), ovulation (LH surge–induced oocyte release), and the luteal phase (corpus luteum secretion of progesterone driving secretory endometrial transformation). Without hCG rescue from a developing embryo, the corpus luteum degenerates (luteolysis), progesterone withdraws, spiral arterioles constrict, and menstruation begins the next cycle. Disruptions at any HPG level—hypothalamic amenorrhea, PCOS, primary ovarian insufficiency—produce characteristic hormonal signatures that can be diagnosed by comparing FSH, LH, estradiol, and progesterone against the normal cycle template.